| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5655910 | Digestive and Liver Disease | 2016 | 6 Pages |
Abstract
Baseline vWF-Ag levels predict outcome of DAA based treatment in HCV-1 patients and identify patients with a risk of SAEs. Therefore vWF-Ag may be an additional marker for selecting patients for interferon free therapeutic regimens.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Karoline Rutter, Alexandra Etschmaier, Monika Ferlitsch, Andreas Maieron, Stephanie Hametner, Thomas Horvatits, Rafael Paternostro, Petra Salzl, Thomas Reiberger, Markus Peck-Radosavljevic, Peter Quehenberger, Harald Hofer, Michael Trauner,